Ascentage Pharma reported a 93% increase in product sales from Olverembatinib in the first half of 2025, reaching US$30.3 million, thanks to expanded NRDL coverage. Lisaftoclax sales commenced in China after approval for CLL/SLL treatment. Registrational Phase III trial for 1L HR MDS cleared by FDA and EMA, with ongoing trials. A top-up placement raised US$190.1 million. Nine registrational clinical trials are in progress, including three cleared by FDA. Investor webcasts in Mandarin and English scheduled. Financial results show revenue at US$32.6 million, with Olverembatinib sales up 93%. Expenses increased for commercialization efforts and development programs. Cash and bank balances increased to US$231.9 million.

Read more at GlobeNewswire: Ascentage Pharma Reports 2025 Interim Unaudited Six Months